Management of cytomegalovirus infection in solid organ transplantation

Nature Reviews Nephrology

Volumn 6, Issue 12, 2010, Pages 711-721

  Kotton, Camille N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; HUMAN; IMMUNOCOMPROMISED PATIENT; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79955009432     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.141     Document Type: Article

References (136)

1. Kotton, C. N. et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89, 779-795 (2010).
2. [No authors listed] KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9 (Suppl. 3), S1-S155 (2009).
3. Humar, A. & Snydman, D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9 (Suppl. 4), S78-S86 (2009).
4. Fishman, J. A. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357, 2601-2614 (2007).
5. Ho, M. Epidemiology of cytomegalovirus infections. Rev. Infect. Dis. 12 (Suppl. 7), S701-S710 (1990).
6. Kanter, J. et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant. Proc. 41, 2156-2158 (2009).
7. Doron, S., Ruthazer, R., Werner, B. G., Rabson, A. & Snydman, D. R. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 81, 697-703 (2006).
8. Corales, R. et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl. Infect. Dis. 2, 133-139 (2000).
9. Goldfarb, N. S. et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71, 242-246 (2001).
10. Hoffmann, T. W. et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J. Med. Genet. 47, 54-58 (2009).
11. Lowance, D. et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340, 1462-1470 (1999).
12. Gane, E. et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350, 1729-1733 (1997).
13. San Juan, R. et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin. Infect. Dis. 47, 875-882 (2008).
14. Ettinger, N. A. et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am. Rev. Respir. Dis. 147, 1017-1023 (1993).
15. Duncan, A. J. et al. Cytomegalovirus infection and survival in lung transplant recipients. J. Heart Lung Transplant. 10, 638-644 (1991).
16. Pescovitz, M. D. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 82, S4-S8 (2006).
17. Falagas, M. E. et al. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin. Infect. Dis. 25, 314-317 (1997).
18. Sagedal, S. et al. Impact of early cytomegalovirus infection and disease on long- term recipient and kidney graft survival. Kidney Int. 66, 329-337 (2004).
19. Streblow, D. N., Orloff, S. L. & Nelson, J. A. Acceleration of allograft failure by cytomegalovirus. Curr. Opin. Immunol. 19, 577-582 (2007).
20. Kliem, V. et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8, 975-983 (2008).
21. Reischig, T. et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87, 436-444 (2009).
22. Razonable, R. R. et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV- mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis. 184, 1461-1464 (2001).
23. Sagedal, S. et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transplant. 2, 850-856 (2002).
24. Dmitrienko, S., Balshaw, R., Machnicki, G., Shapiro, R. J. & Keown, P. A. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines. Transplantation 87, 570-577 (2009).
25. Johnson, R. J., Clatworthy, M. R., Birch, R., Hammad, A. & Bradley, J. A. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation 88, 77-82 (2009).
26. Freeman, R. B. Jr. The ‘indirect’ effects of cytomegalovirus infection. Am. J. Transplant. 9, 2453-2458 (2009).
27. Lautenschlager, I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl. Int. 22, 1031-1040 (2009).
28. Weber, B., Fall, E. M., Berger, A. & Doerr, H. W. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J. Clin. Virol. 14, 173-181 (1999).
29. Seed, C. R. et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 49, 134-145 (2009).
30. Lazzarotto, T., Brojanac, S., Maine, G. T. & Landini, M. P. Search for cytomegalovirus- specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin. Diagn. Lab. Immunol. 4, 483-486 (1997).
31. Humar, A. et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am. J. Transplant. 5, 1065-1070 (2005).
32. Rayes, N. et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann. Transplant. 10, 23-28 (2005).
33. Schroeder, R. et al. Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease. Transplant. Proc. 37, 2781-2783 (2005).
34. Baldanti, F., Lilleri, D. & Gerna, G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237-241 (2008).
35. Gerna, G. et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 75, 1012-1019 (2003).
36. Villa, M. et al. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia. Transplant. Proc. 35, 732-734 (2003).
37. Caliendo, A. M. et al. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J. Clin. Microbiol. 40, 1581-1586 (2002).
38. Lao, W. C. et al. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation. J. Med. Virol. 51, 152-158 (1997).
39. Razonable, R. R. et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J. Infect. Dis. 187, 1801-1808 (2003).
40. Rollag, H. et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin. Microbiol. Infect. 8, 431-434 (2002).
41. Emery, V. C. et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032-2036 (2000).
42. Humar, A. et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 68, 1305-1311 (1999).
43. Humar, A., Kumar, D., Boivin, G. & Caliendo, A. M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J. Infect. Dis. 186, 829-833 (2002).
44. Razonable, R. R. et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73, 968-973 (2002).
45. Tang, W., Elmore, S. H., Fan, H., Thorne, L. B. & Gulley, M. L. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn. Mol. Pathol. 17, 166-173 (2008).
46. Hamprecht, K., Steinmassl, M., Einsele, H. & Jahn, G. Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J. Clin. Virol. 11, 125-136 (1998).
47. Koidl, C., Bozic, M., Marth, E. & Kessler, H. H. Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma? J. Virol. Methods 154, 210-212 (2008).
48. Pang, X. L. et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9, 258-268 (2009).
49. Caliendo, A. M. et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J. Clin. Microbiol. 38, 2122-2127 (2000).
50. Piiparinen, H., Hockerstedt, K., Gronhagen- Riska, C. & Lautenschlager, I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65- antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J. Clin. Virol. 30, 258-266 (2004).
51. Riise, G. C. et al. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 118, 1653-1660 (2000).
52. Westall, G. P, Michaelides, A., Williams, T. J., Snell, G. I. & Kotsimbos, T. C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis. 190, 1076-1083 (2004).
53. Chemaly, R. F. et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J. Clin. Microbiol. 42, 2168-2172 (2004).
54. Gerna, G. et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am. J. Transplant. 9, 1142-1150 (2009).
55. Solans, E. P, Yong, S., Husain, A. N., Eichorst, M. & Gattuso, P. Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study. Diagn. Cytopathol. 16, 350-352 (1997).
56. Ljungman, P, Griffiths, P. & Paya, C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34, 1094-1097 (2002).
57. Lautenschlager, I., Halme, L., Hockerstedt, K., Krogerus, L. & Taskinen, E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl. Infect. Dis. 8, 21-30 (2006).
58. Halme, L. et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS 116, 99-106 (2008).
59. Pillay, D. et al. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 56, 103-108 (1993).
60. Sester, M. et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71, 1287-1294 (2001).
61. Gerna, G. et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6, 2356-2364 (2006).
62. Kumar, D. et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9, 1214-1222 (2009).
63. Radha, R. et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am. J. Transplant. 5, 110-117 (2005).
64. Sester, U. et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant. 5, 1483-1489 (2005).
65. Sester, U. et al. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant. 8, 1486-1497 (2008).
66. Harari, A., Vallelian, F., Meylan, P R. & Pantaleo, G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174, 1037-1045 (2005).
67. Crough, T. & Khanna, R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22, 76-98 (2009).
68. Sester, M., Gartner, B. C. & Sester, U. Monitoring of CMV-specific T-cell levels after organ transplantation. J. Lab. Med. 32, 121-130 (2008).
69. Gandhi, M. K. & Khanna, R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4, 725-738 (2004).
70. Sylwester, A. W. et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673-685 (2005).
71. Einsele, H. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916-3922 (2002).
72. Brestrich, G. et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transplant. 9, 1679-1684 (2009).
73. Plotkin, S. A. et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 114, 525-531 (1991).
74. Pass, R. F. et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191-1199 (2009).
75. Wloch, M. K. et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 197, 1634-1642 (2008).
76. Schleiss, M. R. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr. Opin. Mol. Ther. 11, 572-578 (2009).
77. Bernstein, D. I. et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185, 686-690 (2002).
78. Berencsi, K. et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 183, 1171-1179 (2001).
79. Reap, E. A. et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25, 7441-7449 (2007).
80. Zhong, J., Rist, M., Cooper, L., Smith, C. & Khanna, R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS ONE 3, e3256 (2008).
81. Paya, C. et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4, 611-620 (2004).
82. Humar, A. et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10, 1228-1237 (2010).
83. Luan, F. L. et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J. Am. Soc. Nephrol. 20, 2449-2458 (2009).
84. Razonable, R. R. et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis. 192, 1331-1339 (2005).
85. Hodson, E. M. et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365, 2105-2115 (2005).
86. Arthurs, S. K. et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46, 840-846 (2008).
87. Scemla, A., Kreis, H. & Legendre, C. Less pessimistic long-term results for patients with cytomegalovirus disease. Clin. Infect. Dis. 47, 1360-1361 (2008).
88. Limaye, A. P. et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81, 1645-1652 (2006).
89. Khoury, J. A. et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6, 2134-2143 (2006).
90. Reischig, T. et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8, 69-77 (2008).
91. Kalil, A. C., Levitsk, J., Lyden, E., Stoner, J. & Freifeld, A. G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143, 870-880 (2005).
92. Small, L. N., Lau, J. & Snydman, D. R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis. 43, 869-880 (2006).
93. Levitsky, J. et al. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant. 8, 158-161 (2008).
94. Shiley, K. T. et al. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl. 15, 963-967 (2009).
95. Arthurs, S. K. et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl. 13, 1703-1709 (2007).
96. Ranganathan, K. et al. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J. Heart Lung Transplant. 28, 1050-1056 (2009).
97. Chamberlain, C. E. et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am. J. Transplant. 8, 1297-1302 (2008).
98. Brumble, L. M. et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest 121, 407-414 (2002).
99. San Juan, R. et al. A new strategy of delayed long- term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin. Transplant. 23, 666-671 (2009).
100. Asberg, A. et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7, 2106-2113 (2007).
101. McGavin, J. K. & Goa, K. L. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61, 1153-1183 (2001).
102. Emery, V. C. & Griffiths, P. D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl Acad. Sci. USA 97, 8039-8044 (2000).
103. Chou, S. W. Cytomegalovirus drug resistance and clinical implications. Transpl. Infect. Dis. 3 (Suppl. 2), 20-24 (2001).
104. Sia, I. G. et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect. Dis. 181, 717-720 (2000).
105. Asberg, A. et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transplant. 9, 1205-1213 (2009).
106. Humar, A. et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 67, 94-97 (1999).
107. Shanahan, A., Malani, P. N. & Kaul, D. R. Relapsing cytomegalovirus infection in solid organ transplant recipients. Transpl. Infect. Dis. 11, 513-518 (2009).
108. Eid, A. J., Arthurs, S. K., Deziel, P. J., Wilhelm, M. P. & Razonable, R. R. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 10, 157-161 (2010).
109. Boeckh, M. & Nichols, W. G. Immunosuppressive effects of beta-herpesviruses. Herpes 10, 12-16 (2003).
110. Boivin, G., Goyette, N., Gilbert, C., Humar, A. & Covington, E. Clinical impact of ganciclovir- resistant cytomegalovirus infections in solid organ transplant patients. Transplant. Infect. Dis. 7, 166-170 (2005).
111. Limaye, A. P, Corey, L., Koelle, D. M., Davis, C. L. & Boeckh, M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356, 645-649 (2000).
112. Marfori, J. E., Exner, M. M., Marousek, G. I., Chou, S. & Drew, W. L. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J. Clin. Virol. 38, 120-125 (2007).
113. Li, F. et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin. Infect. Dis. 45, 439-447 (2007).
114. Limaye, A. P Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35, 866-872 (2002).
115. Gilbert, C., Bestman-Smith, J. & Boivin, G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5, 88-114 (2002).
116. Chou, S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18, 233-246 (2008).
117. Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C. & Drew, W. L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188, 32-39 (2003).
118. Gilbert, C. & Boivin, G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49, 873-883 (2005).
119. Boivin, G., Goyette, N., Gilbert, C. & Covington, E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J. Med. Virol. 77, 425-429 (2005).
120. Chou, S., Marousek, G. I., Van Wechel, L. C., Li, S. & Weinberg, A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51, 4160-4162 (2007).
121. Smith, I. L. et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176, 69-77 (1997).
122. Mylonakis, E., Kallas, W. M. & Fishman, J. A. Combination antiviral therapy for ganciclovir- resistant cytomegalovirus infection in solid- organ transplant recipients. Clin. Infect. Dis. 34, 1337-1341 (2002).
123. Ljungman, P. et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97, 388-392 (2001).
124. Biron, K. K. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46, 2365-2372 (2002).
125. Pescovitz, M. D. Maribavir: a new oral anti- cytomegalovirus drug. Future Virol. 3, 435-443 (2008).
126. Winston, D. J. et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111, 5403-5410 (2008).
127. Ozaki, K. S. et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin. Transplant. 21, 675-680 (2007).
128. Shapira, M. Y. et al. Artesunate as a potent antiviral agent in a patient with late drug- resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46, 1455-1457 (2008).
129. Avery, R. K. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr. Opin. Infect. Dis. 21, 433-437 (2008).
130. Levi, M. E., Mandava, N., Chan, L. K., Weinberg, A. & Olson, J. L. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl. Infect. Dis. 8, 38-43 (2006).
131. Battiwalla, M. et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl. Infect. Dis. 9, 28-32 (2007).
132. Mossad, S. B. & Avery, R. K. Second look at leflunomide “failure" to control cytomegalovirus infection in the setting of renal failure. Transpl. Infect. Dis. 9, 260 (2007).
133. Spivey, J. F. et al. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr. Transplant. 11, 312-318 (2007).
134. Vaudry, W. et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am. J. Transplant. 9, 636-643 (2009).
135. Genentech. CYTOVENE®-IV (Ganciclovir Sodium for Injection) [online], http://www.gene.com/gene/products/information/cvtovene/pdf/pi.pdf (2010).
136. Drugs Information. Ganciclovir (Systemic) [online], http://www.drugs.com/mmx/cytovene.html (2010).